CN Patent

CN105267170A — 固体口服延长释放药物剂型

Assigned to Purdue Pharma LP · Expires 2016-01-27 · 10y expired

What this patent protects

本发明涉及包含阿片类镇痛剂的固体口服延长释放药物剂型(例如抗篡改剂型)以及其制备方法、用途和治疗方法。本发明提供一种包含延长释放基质制剂的固体口服延长释放药物剂型，所述延长释放基质制剂包含至少含有以下成分的组合物：(1)基于流变学测量的近似分子量为至少800,000的至少一种聚环氧乙烷；以及(2)选自阿片类镇痛剂的至少一种活性剂，并且其中所述组合物包含至少约80wt％的聚环氧乙烷。

USPTO Abstract

本发明涉及包含阿片类镇痛剂的固体口服延长释放药物剂型(例如抗篡改剂型)以及其制备方法、用途和治疗方法。本发明提供一种包含延长释放基质制剂的固体口服延长释放药物剂型，所述延长释放基质制剂包含至少含有以下成分的组合物：(1)基于流变学测量的近似分子量为至少800,000的至少一种聚环氧乙烷；以及(2)选自阿片类镇痛剂的至少一种活性剂，并且其中所述组合物包含至少约80wt％的聚环氧乙烷。

Drugs covered by this patent

Patent Metadata

Patent number
CN105267170A
Jurisdiction
CN
Classification
—
Expires
2016-01-27
Drug substance claim
No
Drug product claim
No
Assignee
Purdue Pharma LP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.